Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities

  • Kim, Hyun Jung (Department of Pediatrics, Eulji University School of Medicine) ;
  • Lee, Hyo Eun (Department of Pediatrics, Eulji University School of Medicine) ;
  • Yu, Jae Won (Department of Pediatrics, Chungnam University School of Medicine) ;
  • Kil, Hong Ryang (Department of Pediatrics, Chungnam University School of Medicine)
  • Received : 2016.01.09
  • Accepted : 2016.04.11
  • Published : 2016.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Although a significant number of reports on new therapeutic options for refractory Kawasaki disease (KD) such as steroid, infliximab, or repeated intravenous immunoglobulin (IVIG) are available, their effectiveness in reducing the prevalence of coronary artery lesions (CAL) remains controversial. This study aimed to define the clinical characteristics of patients with refractory KD and to assess the effects of adjuvant therapy on patient outcomes. Methods: We performed a retrospective study of 38 refractory KD patients from January 2012 to March 2015. We divided these patients into 2 groups: group 1 received more than 3 IVIG administration+steroid therapy, (n=7, 18.4%), and group 2 patients were unresponsive to initial IVIG and required steroid therapy or second IVIG (n=31, 81.6%). We compared the clinical manifestations, laboratory results, and echocardiographic findings between the groups and examined the clinical utility of additional therapies in both groups. Results: A significant difference was found in the total duration of fever between the groups ($13.0{\pm}4.04days$ in group 1 vs. $8.87{\pm}2.30days$ in group 2; P=0.035). At the end of the follow-up, all cases in group 1 showed suppressed CAL. In group 2, coronary artery aneurysm occurred in 2 patients (6.4%). All the patients treated with intravenous corticosteroids without additional IVIG developed CALs including coronary artery aneurysms. Conclusion: No statistical difference was found in the development of CAL between the groups. Prospective, randomized, clinical studies are needed to elucidate the effects of adjunctive therapy in refractory KD patients.

Keywords

References

  1. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9. https://doi.org/10.1056/NEJM199106063242305
  2. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123: 657-9. https://doi.org/10.1016/S0022-3476(05)80972-2
  3. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9. https://doi.org/10.1016/S0022-3476(96)70447-X
  4. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78. https://doi.org/10.1542/peds.105.6.e78
  5. Lee MS, An SY, Jang GC, Kim DS. A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate. Yonsei Med J 2002;43:527-32. https://doi.org/10.3349/ymj.2002.43.4.527
  6. Imagawa T, Mori M, Miyamae T, Ito S, Nakamura T, Yasui K, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004;163:263-4. https://doi.org/10.1007/s00431-003-1267-y
  7. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7. https://doi.org/10.1016/j.jpeds.2004.12.022
  8. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
  9. Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J Pediatr 2003;142:601-3. https://doi.org/10.1067/mpd.2003.258
  10. Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo: Japanese Ministry of Health and Welfare; 1984.
  11. Royle J, Burgner D, Curtis N. The diagnosis and management of Kawasaki disease. J Paediatr Child Health 2005;41:87-93. https://doi.org/10.1111/j.1440-1754.2005.00555.x
  12. Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010;8:197-203. https://doi.org/10.1586/eri.09.109
  13. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr 2004;163:285-91. https://doi.org/10.1007/s00431-004-1431-z
  14. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71. https://doi.org/10.1161/01.CIR.0000145143.19711.78
  15. Ramesh S, Schwartz SA. Therapeutic uses of intravenous immunoglobulin (IVIG) in children. Pediatr Rev 1995;16:403-10.
  16. Gill V, Doig C, Knight D, Love E, Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005;112:2031-9. https://doi.org/10.1161/CIRCULATIONAHA.105.546150
  17. Ogata S, Bando Y, Kimura S, Ando H, Nakahata Y, Ogihara Y, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol 2009;53:15-9. https://doi.org/10.1016/j.jjcc.2008.08.002
  18. Teraguchi M, Ogino H, Yoshimura K, Taniuchi S, Kino M, Okazaki H, et al. Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: a prospective study. Pediatr Cardiol 2013;34:959-63. https://doi.org/10.1007/s00246-012-0589-9
  19. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990;56:29-36. https://doi.org/10.1016/0090-1229(90)90166-N
  20. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008;153:833-8. https://doi.org/10.1016/j.jpeds.2008.06.011
  21. Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 2012;39: 864-7. https://doi.org/10.3899/jrheum.110877
  22. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. https://doi.org/10.1001/jama.295.19.2275
  23. van Ingen J, Boeree MJ, Dekhuijzen PN, van Soolingen D. Mycobacterial disease in patients with rheumatic disease. Nat Clin Pract Rheumatol 2008;4:649-56.
  24. Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV Jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 2002;8:186-91. https://doi.org/10.1097/00054725-200205000-00005
  25. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348: 601-8. https://doi.org/10.1056/NEJMoa020888
  26. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2013;99:76-82. https://doi.org/10.1136/heartjnl-2012-302126

Cited by

  1. A cross-sectional retrospective study to analyze the underlying causes and clinical characteristics of children with reactive thrombocytosis at a Korean tertiary medical center vol.53, pp.3, 2016, https://doi.org/10.5045/br.2018.53.3.233
  2. Kawasaki Disease: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments vol.3, pp.10, 2021, https://doi.org/10.1002/acr2.11308